SCHEMBL12215331

SCHEMBL12215331

COc1ncc(OC)c2c(C(=O)C(C)=O)c[nH]c12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.58
CYP3A4 P08684 3/20 0.41
CYP2D6 P10635 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C8 P10632 1/20 0.39
CYP2B6 P20813 1/20 0.39
CYP2C19 P33261 1/20 0.39
KCNH2 Q12809 1/20 0.39
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
JAK3 P52333 1/20 0.33
MAP3K7 O43318 1/20 0.33
TAB1 Q15750 1/20 0.33
IKBKB O14920 2/20 0.32
MAP2K1 Q02750 1/20 0.31
CHUK O15111 1/20 0.31
CNR1 P21554 1/20 0.31
CNR2 P34972 1/20 0.31
CLK1 P49759 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1472698 0.89 CYP2C9 (0.61) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
Potassium Ion SCHEMBL7061538 0.88 CYP2C9 (0.57) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
Water SCHEMBL1733706 0.88 CYP2C9 (0.60) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL13119403 0.88 CYP2C9 (0.57) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL12215447 0.85 CYP2C9 (0.44) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL12215466 0.85 CYP2C9 (0.44) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL12215445 0.84 CYP2C9 (0.46) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL12215444 0.84 CYP2C9 (0.43) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL3231262 0.83 CYP2C9 (0.53) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL12215327 0.82 CYP2C9 (0.42) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8039486-B2 Viricides, immunomodulators or HIV entry inhibitors; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-10-18 US disclosed
US-7820820-B2 Method of preparation of azaindole derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2010-10-26 US disclosed
US-7598380-B2 Method of preparation of azaindole derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2009-10-06 US disclosed
US-20080132516-A1 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132516-A1 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES IDO2, IDO1, INMT CYP2C9 888/4885CYP3A4 136/4885CYP2D6 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.